Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
147
-
Total 13F shares, excl. options
-
56.7M
-
Shares change
-
+1.47M
-
Total reported value, excl. options
-
$2.05B
-
Value change
-
+$60.2M
-
Put/Call ratio
-
1.16
-
Number of buys
-
78
-
Number of sells
-
-64
-
Price
-
$36.10
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q3 2022
177 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q3 2022.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 147 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.7M shares
of 77.3M outstanding shares and own 73.26% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (4.9M shares), FMR LLC (4.67M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (4.5M shares), MARSHALL WACE, LLP (2.81M shares), Polar Capital Holdings Plc (2.66M shares), Redmile Group, LLC (2.37M shares), PICTET ASSET MANAGEMENT SA (2.29M shares), Capital World Investors (2.27M shares), PERCEPTIVE ADVISORS LLC (2.12M shares), and LORD, ABBETT & CO. LLC (1.91M shares).
This table shows the top 147 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.